PL2470545T3 - Bezwodne postaci pochodnej pirydyny - Google Patents

Bezwodne postaci pochodnej pirydyny

Info

Publication number
PL2470545T3
PL2470545T3 PL10747619T PL10747619T PL2470545T3 PL 2470545 T3 PL2470545 T3 PL 2470545T3 PL 10747619 T PL10747619 T PL 10747619T PL 10747619 T PL10747619 T PL 10747619T PL 2470545 T3 PL2470545 T3 PL 2470545T3
Authority
PL
Poland
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
pyridine
Prior art date
Application number
PL10747619T
Other languages
English (en)
Polish (pl)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of PL2470545T3 publication Critical patent/PL2470545T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10747619T 2009-08-27 2010-08-25 Bezwodne postaci pochodnej pirydyny PL2470545T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
EP10747619.4A EP2470545B1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
PL2470545T3 true PL2470545T3 (pl) 2014-03-31

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747619T PL2470545T3 (pl) 2009-08-27 2010-08-25 Bezwodne postaci pochodnej pirydyny

Country Status (18)

Country Link
US (1) US8796269B2 (OSRAM)
EP (1) EP2470545B1 (OSRAM)
JP (3) JP2013503134A (OSRAM)
KR (1) KR20120056258A (OSRAM)
CN (1) CN102639536B (OSRAM)
AU (1) AU2010288502B2 (OSRAM)
BR (1) BR112012003435A2 (OSRAM)
CA (1) CA2772168C (OSRAM)
DK (1) DK2470545T3 (OSRAM)
EA (1) EA021411B1 (OSRAM)
ES (1) ES2440938T3 (OSRAM)
IL (1) IL217922A (OSRAM)
IN (1) IN2012DN01292A (OSRAM)
MX (1) MX2012002369A (OSRAM)
PL (1) PL2470545T3 (OSRAM)
SG (1) SG178231A1 (OSRAM)
WO (1) WO2011023733A1 (OSRAM)
ZA (1) ZA201200812B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01292A (OSRAM) * 2009-08-27 2015-06-05 Glaxosmithkline Llc
EP3915560A1 (en) * 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
RS59608B1 (sr) * 2015-05-18 2020-01-31 Nerre Therapeutics Ltd Antagonist nk-1/nk-3 receptora za lečenje valunga
US11028099B2 (en) * 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators
RS65257B1 (sr) 2018-03-14 2024-03-29 Kandy Therapeutics Ltd Nova farmaceutska formulacija koja sadrži dvojne antagoniste receptora nk-1/nk-3
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
AU2020381762A1 (en) 2019-11-15 2022-06-02 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
CA2514037C (en) * 2003-01-31 2012-03-13 F. Hoffmann-La Roche Ag Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
IN2012DN01292A (OSRAM) * 2009-08-27 2015-06-05 Glaxosmithkline Llc
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
JP6404186B2 (ja) 2018-10-10
KR20120056258A (ko) 2012-06-01
SG178231A1 (en) 2012-03-29
EP2470545A1 (en) 2012-07-04
EA021411B1 (ru) 2015-06-30
IL217922A (en) 2016-06-30
DK2470545T3 (da) 2014-01-13
IL217922A0 (en) 2012-03-29
MX2012002369A (es) 2012-03-29
ES2440938T3 (es) 2014-01-31
JP2016000739A (ja) 2016-01-07
JP2013503134A (ja) 2013-01-31
US20120157450A1 (en) 2012-06-21
WO2011023733A1 (en) 2011-03-03
EA201270302A1 (ru) 2012-07-30
CN102639536B (zh) 2015-03-18
US8796269B2 (en) 2014-08-05
EP2470545B1 (en) 2013-10-09
CA2772168A1 (en) 2011-03-03
CA2772168C (en) 2019-01-08
AU2010288502A1 (en) 2012-02-23
BR112012003435A2 (pt) 2016-02-23
AU2010288502B2 (en) 2013-12-12
CN102639536A (zh) 2012-08-15
ZA201200812B (en) 2013-03-27
JP2017193564A (ja) 2017-10-26
IN2012DN01292A (OSRAM) 2015-06-05

Similar Documents

Publication Publication Date Title
ZA201105479B (en) Pyridine derivative
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
IL220616A0 (en) Novel 3 - hydroxy - 5 - arylisothiazole derivative
IL235745A (en) Annotated 2-Aminopyridine
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
EP2495238A4 (en) NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
GB0914661D0 (en) System for derermination of downhole position
SI2433940T1 (sl) Spiroimidazolonski derivat
PL2444395T3 (pl) Podstawiona pochodna izochinoliny
EP2397480A4 (en) DIAZEPINEDIONE DERIVATIVE
IL217922A0 (en) Anhydrate forms of a pyridine derivative
SI2155200T1 (sl) Kristalinična oblika kabamoil-cikloheksanskega derivata
AP3169A (en) A method of improved positioning
IL213466A0 (en) Spiroindolinone pyridine derivative
ZA201204063B (en) 2-pyridone compounds
ZA201202899B (en) 5-hydroxypyrimidine-4-carboxamide derivative
IL214293A0 (en) Dihydroquinolinone derivatives
ZA201107617B (en) Carbinol compound having heterocyclic linker
GB0918358D0 (en) Wellbore completion
GB0918922D0 (en) Aminopyridine derivatives
IL214028A0 (en) A novel cyanopyrimidine derivative
EP2476682A4 (en) 8-oxodihydropurine DERIVATIVE
IL210777A0 (en) Crystalline forms of a pyridine derivative
GB0921967D0 (en) Novel Aryloxyanilide Derivatives